At a glance
- Originator Kyowa Hakko
- Class Antihyperlipidaemics; Dibenzoxepins; Small molecules
- Mechanism of Action Sterol O-acyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Atherosclerosis; Hyperlipidaemia
Most Recent Events
- 13 Jul 1999 No-Development-Reported for Atherosclerosis in Japan (Unknown route)
- 13 Jul 1999 No-Development-Reported for Hyperlipidaemia in Japan (Unknown route)
- 11 Dec 1997 Preclinical development for Atherosclerosis in Japan (Unknown route)